Abstract

The objectives of this program are: 1. To conduct collaborative clinical research in the therapy of malignant disease emphasizing the multidisciplinary application of chemotherapy, radiation therapy and surgical modalities monitored by careful pathologic review to the management of patients with cancer. The studies proposed include Phase I (new drug, toxicity-dose relationships); Phase II (tumor response) and Phase III (optimal scheduling of treatments and response) protocols. The goal is to provide optimal patient care and service while evaluating and attempting to improve all phases of cancer patient care. 2. To encourage and foster the exploration, development and use of newer and/or infrequently used therapeutic modalities, either singly (hyperthermia, regional perfusion, tumor embolization e.g.) or in multidisciplinary programs (hyperthermia plus irradiation, chemotherapy plus hyperthermia, regional perfusion, chemotherapy combined with surgery and/or radiation therapy) to improve cure rates and prolong survival.

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
5U10CA013238-16
Application #
3556175
Study Section
Cancer Clinical Investigation Review Committee (CCI)
Project Start
1978-01-01
Project End
1988-06-30
Budget Start
1987-01-01
Budget End
1988-06-30
Support Year
16
Fiscal Year
1987
Total Cost
Indirect Cost

  Institution

Name
University of Utah
Department
Type
Schools of Medicine
DUNS #
City
Salt Lake City
State
UT
Country
United States
Zip Code
84112

  Publications

Fanidi, Anouar; Ferrari, Pietro; Biessy, Carine et al. (2015) Adherence to the World Cancer Research Fund/American Institute for Cancer Research cancer prevention recommendations and breast cancer risk in the Cancer de Màma (CAMA) study. Public Health Nutr 18:3337-48
Erba, Harry P; Othus, Megan; Walter, Roland B et al. (2014) Four different regimens of farnesyltransferase inhibitor tipifarnib in older, untreated acute myeloid leukemia patients: North American Intergroup Phase II study SWOG S0432. Leuk Res 38:329-33
Deininger, Michael W; Kopecky, Kenneth J; Radich, Jerald P et al. (2014) Imatinib 800 mg daily induces deeper molecular responses than imatinib 400 mg daily: results of SWOG S0325, an intergroup randomized PHASE II trial in newly diagnosed chronic phase chronic myeloid leukaemia. Br J Haematol 164:223-32
Fedirko, Veronika; Torres-Mejía, Gabriela; Ortega-Olvera, Carolina et al. (2012) Serum 25-hydroxyvitamin D and risk of breast cancer: results of a large population-based case-control study in Mexican women. Cancer Causes Control 23:1149-62
Devaraj, Bikash; Lee, Aaron; Cabrera, Betty L et al. (2010) Relationship of EMAST and microsatellite instability among patients with rectal cancer. J Gastrointest Surg 14:1521-8
Beasley, Jeannette M; Coronado, Gloria D; Livaudais, Jennifer et al. (2010) Alcohol and risk of breast cancer in Mexican women. Cancer Causes Control 21:863-70
Rivkin, Saul E; Green, Stephanie J; Lew, Danika et al. (2003) Adjuvant chemotherapy with cyclophosphamide, methotrexate, and 5-fluorouracil, vincristine, and prednisone compared with single-agent L-phenylalanine mustard for patients with operable breast carcinoma and positive axillary lymph nodes: 20-year results of Cancer 97:21-9
Taylor, Sarah A; Rankin, Cathryn; Townsend, Jeannette J et al. (2002) Phase II trial of amonafide in central nervous system tumors: a Southwest Oncology Group study. Invest New Drugs 20:113-5
Smith Jr, J A; Crawford, E D; Paradelo, J C et al. (1997) Treatment of advanced bladder cancer with combined preoperative irradiation and radical cystectomy versus radical cystectomy alone: a phase III intergroup study. J Urol 157:805-7; discussion 807-8
Hewlett, J; Kopecky, K J; Head, D et al. (1995) A prospective evaluation of the roles of allogeneic marrow transplantation and low-dose monthly maintenance chemotherapy in the treatment of adult acute myelogenous leukemia (AML): a Southwest Oncology Group study. Leukemia 9:562-9

Showing the most recent 10 out of 33 publications